pojo-accessibility domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/wwwclexiocom/wp-includes/functions.php on line 6121acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/wwwclexiocom/wp-includes/functions.php on line 6121
We are developing innovative therapies to address patients’ unmet needs in Major Depressive Disorder, Schizophrenia and Bipolar Depression.
Our lead drug candidate (CLE-100) is currently being tested in Phase 2 multicenter studies in the United States.
Our lead preclinical candidate (CLE-905) has recently completed IND enabling activities, with First-In-Human Phase 1 study expected to start in the coming months.
Our multidisciplinary team brings years of experience in the Pharmaceutical and Biotech industries and encompasses end-to-end drug development expertise, from early stage to advanced clinical stages, and regulatory approvals.
Individually and as a team, we are excited every day to use our expertise to innovate, integrate, apply, and develop new and effective solutions for people affected by mental health disorders.
Learn MoreWe are a multi-asset company with a rich and growing pipeline, from preclinical to Phase 2 development stages.
Developing a new treatment paradigm for patients suffering from Major Depressive Disorder
Developing a potent M1/M4 preferential muscarinic agonist for Schizophrenia
Developing a novel NMDA antagonist for Bipolar Depression
